Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35063
Conference/Presentation Title: | IgD myeloma: A unique subtype with unclear prognostic significance. | Authors: | Low M. ;Grigoriadis G. ;Vilcassim S.;Fedele P. ;Shaw B. | Institution: | (Shaw, Fedele, Vilcassim, Grigoriadis, Low) Monash Health (Vilcassim, Low) Monash University, Clayton, Australia | Presentation/Conference Date: | 9-Oct-2020 | Copyright year: | 2020 | Publisher: | Blackwell Publishing Ltd | Publication information: | British Journal of Haematology. Conference: 60th Annual Scientific Meeting of the British Society for Haematology. Birmingham United Kingdom. 189 (Supplement 1) (pp 247), 2020. Date of Publication: April 2020. | Abstract: | Aim: IgD myeloma is a rare plasma cell dyscrasia which is traditionally reported to have a poor outcome compared to patients with other types of M protein. This is thought to be due to higher rates of renal failure, chemotherapy resistance and a more aggressive clinical course. Recent studies have reported conflicting evidence into the survival outcomes of patients with IgD myeloma (Wang GR, Sun WJ et al. 2016, Chen L, Fan F et al. 2019). We therefore aimed to analyse the presentation and prognosis of IgD myeloma in a local cohort of patients in the era of novel therapies. Method(s): Eight patients with an IgD M protein were identified from Monash Medical Centre, Victoria, based on serum electrophoresis records in patients between 2013 and 2018. Retrospective data were collected in regards to M-protein type and size, biochemical and bone marrow analysis at presentation, renal function, co-morbidities and treatment received. Result(s): Median age at diagnosis was 75.5 years of age (range 51-83 years old). 50% presented with anaemia and 75% presented with renal failure with one patient requiring dialysis. The majority had high serum-free light chains at diagnosis with 87.5% having affected light chain above 1000 mg/l. All patients had ISS stage 3, 62.5% had R-ISS stage 3 disease at diagnosis. A single patient had smouldering myeloma without a myeloma defining event after 24 months of observation. Of the remaining patients, 85% received bortezomibbased induction, and 15% received thalidomide-based induction. Only one patient proceeded to autologous transplant. Overall survival in IgD myeloma patients was not statistically different from non-IgD myeloma patients (median 40 vs. 53 months; P = 0.332). Conclusion(s): IgD myeloma remains a rare plasma cell dyscrasia and presents commonly with high serum-free light chains, renal disease and anaemia. In our cohort, survival did not appear worse than non-IgD myeloma patients. | Conference Start Date: | 2020-04-27 | Conference End Date: | 2020-04-29 | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bjh.16638 | ISSN: | 1365-2141 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35063 | Type: | Conference Abstract | Subjects: | electrophoresis female human human tissue International Staging System kidney failure light chain middle aged overall survival plasma cell dyscrasia prognosis retrospective study *smoldering multiple myeloma sun endogenous compound *immunoglobulin D M protein thalidomide kidney function male adult aged anemia bone marrow cancer patient *cancer prognosis cancer staging cancer survival chemotherapy clinical article cohort analysis comorbidity conference abstract controlled study dialysis drug therapy controlled study dialysis drug therapy electrophoresis female human human tissue International Staging System kidney failure kidney function light chain male middle aged overall survival plasma cell dyscrasia prognosis retrospective study *smoldering multiple myeloma cancer patient bone marrow anemia aged adult sun *cancer prognosis cancer staging cancer survival chemotherapy clinical article cohort analysis comorbidity conference abstract |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Conferences |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.